Michael Wang, MD

@michaelwangmd @NICEComms are taking away our only Car T Treatment here in the UK! 🥹 @tobyeyre82 @graham74GC @bloodcancer_uk @LymphomaAction @wesstreeting

Have a great weekend!

Both auto or allo CAR T cells are made ex vivo, outside of human body in the lab. An exciting new tech is to bypass all the limitations of ex vivo manufacture by directly infuse the lentivirus vector into the blood and let the CAR T cells to be made inside the patient’s body.

To overcome limitations of auto CAR T cells, many tries to make allogeneic CAR T cells, T cells from other sources such as from a healthy donor. But allo CAR T cells are so far not as efficacious. Some think that allo T cells could never match auto T cells by biological nature.

Currently approved CAR T therapies on lymphoma are made from the patient’s blood T cells, autologous CAR T cells. They are potent but at times toxic. Making CAR T cells from each patient is labor-intensive, costly and time consuming. There are also CAR T cell manufacture failures

Terrific article in the ⁦@washingtonpost⁩ on advances in #Myeloma that we ⁦⁦@JNJInnovMed⁩ have been leading. ⁦@End_myeloma⁩ featured in the article! #MyCompany washingtonpost.com/health/2026/01…

First clinic in 2026 today, it is going to be an exciting year for research endeavors in mantle cell lymphoma. Stay tuned!

As we enter 2026, I extend my sincere wishes to my patients, colleagues, and friends. May the coming year bring health, joy and steady progress in both science and life. Thank you for your trust, your collaboration, and your support on this journey!

Happy holidays!

Sonrotoclax is a new small molecule inhibitor of Bcl-2, a protein that helps MCL cells to survive. Our data indicates its efficacy and tolerability. It is a major advance in MCL. Now we have another great option add to the long list of therapies. Congratulations to our patients!

CONGRESS | #ASH25 | PRESENTATION Michael Wang presents preliminary data from a phase I/II study evaluating sonrotoclax monotherapy in patients with R/R MCL (N = 125). AEs were manageable and reversible with no DLTs. R2PD was determined to be 320 mg QD. Most common Grade ≥3 TEAEs were hematologic toxicities and infections. ORR was 52.4% with a CR rate of 15.5%. Median time to response was 1.9 months. ORR benefit was consistent across high-risk patients. Median PFS was 6.5 months, median OS was not reached. Median DoR was 15.8 months. Follow our live feed for more updates: loom.ly/POS6cqk Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website. #lymphoma #lymsm #MedicalCongress @michaelwangmd @MDAndersonnews

CONGRESS | #ASH25 | PRESENTATION Michael Wang shares final update from the phase I/II BRUIN study of pirtobrutinib in patients with MCL (N = 166). ORR was 49.3% in patients who received prior cBTKi (n = 152) and 85.7% in cBTKi-naïve patients (n = 14). mDoR was 21.6 months and 42.7 months, respectively. Most common AEs were fatigue, diarrhea, dyspnea, anemia and decreased platelet counts. Grade ≥3 TRAEs included anemia, decreased platelet counts and fatigue. Follow our live feed for more updates: loom.ly/POS6cqk Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website. #lymphoma #lymsm #MedicalCongress @michaelwangmd @MDAndersonnews

Our Dr. Michael Wang presented the results of two studies for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) at #ASH25. In one, he and his team found Sonrotoclax to be a promising option in those previously treated with a bruton tyrosine kinase (BTK) inhibitor. The other showed that Pirtobrutinib continues to demonstrate efficacy in heavily pre-treated patients, regardless of whether they had previously received a cBTK inhibitor. @michaelwangmd #EndCancer

Day 2 at ASH conference, I am getting ready to present that noncornical TCA cycle mode switch determines the fate of MCL DTP cells. A lab study on a new reversible cell model to explain drug resistance.

In this long weekend, I plan to do some relaxation and prepare for ASH presentations, I wish you a happy Thanksgiving!

Sonrotoclax BTKi-exposed R/R MCL #ASH25 - 103 pts, 40% bulky, 16% 2+ prior BTKi - ORR 53% (CR 15%), median TTR 2 mo - mPFS 6.5 mo, mOS NR - 31% stayed on tx, 14% d/c d/t AEs, 13% G5 AEs (!!) TEAEs led to death in 15 pts! Hopefully will see more data in presentation. #lymsm

BRUIN final update: pirto MCL #ASH25 - 166 pts: 84% refractory prior cBTKi, 9% prior CAR - prior cBTKi: ORR 49% (CR 16%), mDOR 22 mo - mPFS 5.6 mo, mOS 24 mo - G3+ infx 21%, all-grade afib 4%, 8% G5 AEs - 43% remain on tx cBTKi naive did better overall. Seeking TP53 data. #lymsm

I am looking forward to the American Hematology Society annual conference in early December. I’ll be presenting 4 projects with new data on novel therapies. One of them on Sonrotoclax, a brand new Bcl-2 inhibitor!

Have a great weekend!

Have a great weekend!